Monebo Technologies Obtains FDA Clearance
to Market Interpretive ECG Algorithm
Unique Algorithm used to automatically analyze and interpret ECG signals for up to 16 heart rhythm disorders, yet can be easily embedded in portable devices
Austin, TX, April 20, 2007: Monebo Technologies, Inc. today announced that its Interpretive ECG Algorithm is now available, following clearance by the United States Food and Drug Administration (FDA). The algorithm is used for the assessment of heart arrhythmias using ambulatory ECG data, and provides the most comprehensive arrhythmia analysis and interpretation available in a multiuse algorithm. It will be integrated into individual ambulatory ECG monitoring devices where it will trigger the device to begin recording based on the identification of certain heart rhythms, and also will be used to interpret the ECG signal once it is transmitted to a centralized call center, providing a high level of accuracy while increasing the efficiency of the interpretation process. The technology will be licensed to medical device companies worldwide for incorporation into products that monitor cardiac electrical activity.
Based on Monebo’s proprietary technology, the algorithm is designed to analyze the signal on a beat-by-beat basis, identify the key components of the ECG, and apply specific rules for the identification of cardiac arrhythmias. Because it is utilized in small, portable devices, it employs specialized processes that result in minimal processing time and resource requirements, while maximizing power management and battery life. The product features QRS and Ventricular Ectopic Beat detection, QRS feature extraction, interval measurement, heart rate measurement, and rhythm analysis for up to sixteen leads of captured data.
“We are excited to release this innovative technology to our Customers,” said Dale Misczynski, President and CEO of Monebo. “The combination of reliable QRS detection, extensive rhythm interpretation and interval measurements in a compact algorithm offer our partners an opportunity to design novel devices that will capitalize on our algorithm’s benefits. Additionally, the accuracy and speed of the algorithm will enable centralized call centers to automate some of their processes, making them more efficient. We will continue to push the limits of our technology in an effort to help our Customers develop better products for the cardiology community.”